Abstract:One in 7 Americans are diagnosed with migraine disease, a leading cause of global disability, lost productivity in the workforce, and the disruption of personal relationships. Recent advancements in migraine treatment have introduced novel therapies that specifically target the calcitonin-gene-related-peptide (CGRP) pathway, a key player in migraine pathophysiology. These groundbreaking migraine-specific therapies exhibit efficacy in reducing the burden of migraine disease. However, despite the emergence of novel therapies (NTs), clinicians are more likely to treat patients with preventive standard of care (SOC) pharmaceuticals such as amitriptyline and topiramate for migraine prevention. Although these SOC options are effective, they often elicit adverse effects that are intolerable for many patients, such as concentration difficulties, fatigue, and weight gain. As a result, patients frequently opt to discontinue SOC preventive treatments, leaving them ensnared in persistent pain and susceptible to medication overuse. In this case, we discuss when, why, and how to introduce these novel therapies into practice and the impact they can have on the quality of life of patients suffering from migraine disease.

Migraine Treatment: When, Why, and How to Introduce Antimigraine Therapies